Clinical Studies

TEST

fgfdjyggh

Study 1 – LEAP-3 Study

Jan Buitelaar
Jan Buitelaar

Lead of study

Longitudinal European Autism Project (LEAP) wave-3
The overall aim of this multi-centre longitudinal case-control study is to identify and validate biomarkers and methodologies (neuroimaging, eye tracking, cognition, biochemistry, metabalomics, genomics, etc.) that can be used to stratify patient groups and that predict clinical outcome of patients with ASD.

Clinical Centres: Radboud University, King’s College London, University of Cambridge, University Medical Centrum Utrecht, Central Institute of Mental Health

Study 2 – EPILEPSY

Jan Buitelaar
Jan Buitelaar

Lead of study

AIMS-2-EPILEPSY Study
The overall aim of this multi-centre longitudinal case-control study is to identify and validate biomarkers and methodologies (neuroimaging, eye tracking, cognition, biochemistry, metabalomics, genomics, etc.) that can be used to stratify patient groups and that predict clinical outcome of patients with ASD.

Clinical Centres: Radboud University, King’s College London, University of Cambridge, University Medical Centrum Utrecht, Central Institute of Mental Health

Study 3 – PIP

Jan Buitelaar
Jan Buitelaar

Lead of study

Preschool Brain Imaging and Behaviour Project
The overall aim of this multi-centre longitudinal case-control study is to identify and validate biomarkers and methodologies (neuroimaging, eye tracking, cognition, biochemistry, metabalomics, genomics, etc.) that can be used to stratify patient groups and that predict clinical outcome of patients with ASD.

Clinical Centres: Radboud University, King’s College London, University of Cambridge, University Medical Centrum Utrecht, Central Institute of Mental Health

Study 4 – Phenocades

Jan Buitelaar
Jan Buitelaar

Lead of study

Identifying translational biomarkers and phenotypic cascades that predict dimensional variation in social communication and restrictive behaviour in development.
The overall aim of this multi-centre longitudinal case-control study is to identify and validate biomarkers and methodologies (neuroimaging, eye tracking, cognition, biochemistry, metabalomics, genomics, etc.) that can be used to stratify patient groups and that predict clinical outcome of patients with ASD.

Clinical Centres: Radboud University, King’s College London, University of Cambridge, University Medical Centrum Utrecht, Central Institute of Mental Health

Study 5

Jan Buitelaar
Jan Buitelaar

Lead of study

Longitudinal European Autism Project (LEAP) wave-3
The overall aim of this multi-centre longitudinal case-control study is to identify and validate biomarkers and methodologies (neuroimaging, eye tracking, cognition, biochemistry, metabalomics, genomics, etc.) that can be used to stratify patient groups and that predict clinical outcome of patients with ASD.

Clinical Centres: Radboud University, King’s College London, University of Cambridge, University Medical Centrum Utrecht, Central Institute of Mental Health

Study 6 – neonatal

Jan Buitelaar
Jan Buitelaar

Lead of study

Longitudinal European Autism Project (LEAP) wave-3
The overall aim of this multi-centre longitudinal case-control study is to identify and validate biomarkers and methodologies (neuroimaging, eye tracking, cognition, biochemistry, metabalomics, genomics, etc.) that can be used to stratify patient groups and that predict clinical outcome of patients with ASD.

Clinical Centres: Radboud University, King’s College London, University of Cambridge, University Medical Centrum Utrecht, Central Institute of Mental Health

Study 7 – Fetal

Jan Buitelaar
Jan Buitelaar

Lead of study

Longitudinal European Autism Project (LEAP) wave-3
The overall aim of this multi-centre longitudinal case-control study is to identify and validate biomarkers and methodologies (neuroimaging, eye tracking, cognition, biochemistry, metabalomics, genomics, etc.) that can be used to stratify patient groups and that predict clinical outcome of patients with ASD.

Clinical Centres: Radboud University, King’s College London, University of Cambridge, University Medical Centrum Utrecht, Central Institute of Mental Health

Study 8 – outcome measures

Jan Buitelaar
Jan Buitelaar

Lead of study

Longitudinal European Autism Project (LEAP) wave-3
The overall aim of this multi-centre longitudinal case-control study is to identify and validate biomarkers and methodologies (neuroimaging, eye tracking, cognition, biochemistry, metabalomics, genomics, etc.) that can be used to stratify patient groups and that predict clinical outcome of patients with ASD.

Clinical Centres: Radboud University, King’s College London, University of Cambridge, University Medical Centrum Utrecht, Central Institute of Mental Health

Study 9 – SynaG

Jan Buitelaar
Jan Buitelaar

Lead of study

Longitudinal European Autism Project (LEAP) wave-3
The overall aim of this multi-centre longitudinal case-control study is to identify and validate biomarkers and methodologies (neuroimaging, eye tracking, cognition, biochemistry, metabalomics, genomics, etc.) that can be used to stratify patient groups and that predict clinical outcome of patients with ASD.

Clinical Centres: Radboud University, King’s College London, University of Cambridge, University Medical Centrum Utrecht, Central Institute of Mental Health

Study 10 – Shiftability 1

Jan Buitelaar
Jan Buitelaar

Lead of study

Longitudinal European Autism Project (LEAP) wave-3
The overall aim of this multi-centre longitudinal case-control study is to identify and validate biomarkers and methodologies (neuroimaging, eye tracking, cognition, biochemistry, metabalomics, genomics, etc.) that can be used to stratify patient groups and that predict clinical outcome of patients with ASD.

Clinical Centres: Radboud University, King’s College London, University of Cambridge, University Medical Centrum Utrecht, Central Institute of Mental Health

Study 11 – Shiftability 2

Jan Buitelaar
Jan Buitelaar

Lead of study

Longitudinal European Autism Project (LEAP) wave-3
The overall aim of this multi-centre longitudinal case-control study is to identify and validate biomarkers and methodologies (neuroimaging, eye tracking, cognition, biochemistry, metabalomics, genomics, etc.) that can be used to stratify patient groups and that predict clinical outcome of patients with ASD.

Clinical Centres: Radboud University, King’s College London, University of Cambridge, University Medical Centrum Utrecht, Central Institute of Mental Health

Study 12 – Fast Fail Trial 1

Jan Buitelaar
Jan Buitelaar

Lead of study

Longitudinal European Autism Project (LEAP) wave-3
The overall aim of this multi-centre longitudinal case-control study is to identify and validate biomarkers and methodologies (neuroimaging, eye tracking, cognition, biochemistry, metabalomics, genomics, etc.) that can be used to stratify patient groups and that predict clinical outcome of patients with ASD.

Clinical Centres: Radboud University, King’s College London, University of Cambridge, University Medical Centrum Utrecht, Central Institute of Mental Health

Study 13 – Fast Fail Trial 2

Jan Buitelaar
Jan Buitelaar

Lead of study

Longitudinal European Autism Project (LEAP) wave-3
The overall aim of this multi-centre longitudinal case-control study is to identify and validate biomarkers and methodologies (neuroimaging, eye tracking, cognition, biochemistry, metabalomics, genomics, etc.) that can be used to stratify patient groups and that predict clinical outcome of patients with ASD.

Clinical Centres: Radboud University, King’s College London, University of Cambridge, University Medical Centrum Utrecht, Central Institute of Mental Health

Study 14 – RCT 1 & RCt 2

Jan Buitelaar
Jan Buitelaar

Lead of study

Longitudinal European Autism Project (LEAP) wave-3
The overall aim of this multi-centre longitudinal case-control study is to identify and validate biomarkers and methodologies (neuroimaging, eye tracking, cognition, biochemistry, metabalomics, genomics, etc.) that can be used to stratify patient groups and that predict clinical outcome of patients with ASD.

Clinical Centres: Radboud University, King’s College London, University of Cambridge, University Medical Centrum Utrecht, Central Institute of Mental Health